Hello everyone,
A quick question: would analyst be interested in reports (moderately priced) that analyze clinical trials (design and results) and that give a probability of approval with regards to biotech companies they are covering? Would it be easier, cheaper and more practical than to interview experts?
Thanks!
that's what we do...
The docs we speak to only tell us whether the MoA is interesting or they'd use the drug in the clinic
Would you be interested in getting a second opinion on your analysis? If the reports are written by experts?
for me, no. I am an expert/PhD. Maybe for teams that are MBA heavy, but they are more rare in biotech
Thanks a lot for your answers! They were really informative
delete
Illo atque voluptas debitis quisquam provident pariatur. Dicta numquam molestiae veritatis ut minima consectetur odit. Nam eos quo ipsa consequatur a fuga.
Iste qui quas et in vel distinctio. Eum deserunt quia praesentium maxime tempora sint dignissimos. Aut aut qui sapiente animi.
Maxime id ut eum. Consectetur ut vel facilis est. Sapiente itaque harum consequuntur. Natus et voluptatem earum autem molestias placeat. Dolores facilis et non molestiae.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...